Skip to main content
PMVP
NASDAQ Life Sciences

Rezatapopt Posts 48% ORR in Pivotal Ovarian Analysis; PMV Pharma Targets Q1 2027 NDA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.876
Mkt Cap
$66.168M
52W Low
$0.66
52W High
$1.91
52W Position info
33% above low
Off High info
54% below high
Rel. Volume info
6.0× avg
Market data snapshot near publication time

PMVP sits 33% above its 52-week low of $0.66 on elevated volume (6.0× avg).

Summary

PMV Pharma reported the pivotal Phase 2 primary analysis of rezatapopt, showing a 48% confirmed response rate and 10.4-month median duration of response in 65 platinum-resistant ovarian cancer patients, plus a 36% ORR across 168 patients in eight tumor types. An NDA for accelerated approval is planned for Q1 2027.


Key Events · Product Development and Regulatory · PMVP

  • Pivotal Ovarian Cohort Shows 48% ORR

    In the 65-patient primary analysis population of platinum-resistant/refractory ovarian cancer, investigator-assessed confirmed ORR was 48% (31/65, one CR and 30 PRs), with a 10.4-month median duration of response and an 83% disease control rate.

  • Broad Activity Across 168 Patients

    Across all cohorts, the overall population showed a 36% ORR (61/168, including four CRs) and an 8.1-month median duration of response; by cohort, ORRs were ovarian 45% (45/101), endometrial 45% (5/11), lung 21% (4/19), breast 17% (3/18) and other solid tumors 21% (4/19).

  • Biomarker Confirms On-Target Effect

    Of 50 patients with ctDNA data, 90% (45/50) achieved at least a 50% reduction in TP53 Y220C variant allele frequency within 3-6 weeks of starting treatment.

  • Manageable Safety, 6% Discontinuation

    Treatment-related adverse events were mostly Grade 1 or 2, individual Grade 3 TRAE rates were at or below 7.2%, and 11 patients (6%), including seven ovarian patients, discontinued due to TRAEs.


Analysis · PMVP · Life Sciences

The dataset PMV Pharma intends to file on is now in hand: the primary analysis of the registrational Phase 2 PYNNACLE trial. In 65 platinum-resistant/refractory ovarian cancer patients — a group with few remaining options after a median of four prior lines of therapy — rezatapopt delivered a 48% confirmed response rate, a 10.4-month median duration of response and an 83% disease control rate. Activity was not confined to one cohort: the 36% ORR across all 168 evaluable patients in eight tumor types, together with a 90% ctDNA response rate, points to on-target mechanism rather than a single-cohort fluke. Safety looks manageable, with individual Grade 3 treatment-related events at or below 7.2% and 6% of patients discontinuing for toxicity. Management reiterated an NDA submission for accelerated approval in Q1 2027, and that filing is now the single event determining whether this asset has commercial value. The risk is concentrated there: accelerated approval would rest on this single-arm data, and the company had $108.5 million in cash as of the last quarterly report, so the filing timeline and any FDA pushback matter more than the response rate itself.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PMVP was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.2M. The 52-week trading range was $0.66 to $1.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PMVP - Latest Insights

PMVP
Nov 20, 2026, 10:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.8918 info
Change: -$0.3082 (-26%) info
Market Cap: $66.168M info
PMVP
Nov 10, 2026, 8:02 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $0.8918 info
Change: -$0.3582 (-29%) info
Market Cap: $66.168M info
PMVP
Nov 10, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $0.8918 info
Change: -$0.3677 (-29%) info
Market Cap: $66.168M info
PMVP
Sep 01, 2026, 6:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.8918 info
Change: -$0.3782 (-30%) info
Market Cap: $66.168M info
PMVP
Sep 01, 2026, 6:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.8918 info
Change: -$0.3782 (-30%) info
Market Cap: $66.168M info